2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase

Carbonic Anhydrase

Carbonate dehydratase

Carbonic Anhydrase

Related Products

PDF 0.73 MB

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16726R
    Polmacoxib (Standard)
    		Inhibitor
    Polmacoxib (Standard) is the analytical standard of Polmacoxib. This product is intended for research and analytical applications. Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonic anhydrase. Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models.
    Polmacoxib (Standard)
  • HY-B0588AS
    Brinzolamide-d5 hydrochloride
    Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride[1]. Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research[2][3].
    Brinzolamide-d<sub>5</sub> hydrochloride
  • HY-19213A
    L-693612 hydrochloride
    		Inhibitor
    L-693612 hydrochloride (Compd 1) is an orally active and topical carbonic anhydrase inhibitor.
    L-693612 hydrochloride
  • HY-147799
    hCA XII/II/IX-IN-1
    		Inhibitor
    hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonic anhydrase (hCA) inhibitor with IC50 values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity.
    hCA XII/II/IX-IN-1
  • HY-147956
    hCA VB-IN-1
    		Inhibitor
    hCA VB-IN-1 (compound 15) is a potent and selective hCA VB (carbonic anhydrase) inhibitor, with a KI of 515.7 nM.
    hCA VB-IN-1
  • HY-146207
    HCAIX-IN-2
    		Inhibitor
    HCAIX-IN-2 (compound 9d) is a selective carbonic anhydrase inhibitor with the Ki values of 24.6 nM and 45.3 nM for hCA IX and hCA XII, respectively.
    HCAIX-IN-2
  • HY-144268
    hCAII-IN-7
    		Inhibitor
    hCAII-IN-7 (Compound R-13) is a potent human carbonic anhydrase (hCA) inhibitor with Kis of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively.
    hCAII-IN-7
  • HY-146979
    hA2A/hCA XII modulator 1
    		Inhibitor
    hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonic anhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research.
    hA2A/hCA XII modulator 1
  • HY-150572
    CDK2-IN-11
    		Inhibitor
    CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC50 of 6.4 μM, and KI values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer.
    CDK2-IN-11
  • HY-W424792A
    O-Desmethyl Brinzolamide hydrochloride
    		Inhibitor
    O-Desmethyl Brinzolamide hydrochloride (compound 6a), an active metabolite of Brinzolamide, is a carbonic anhydrase (CA) inhibitor with a Kd of 0.136 nM for CA II and an IC50 of 165 nM for CA IV.
    O-Desmethyl Brinzolamide hydrochloride
  • HY-158372
    hCA I-IN-3
    		Inhibitor
    hCA I-IN-3 (compound 24), an aryl ether derivative, is a potent carbonic anhydrase inhibitor. hCA I-IN-3 can inhibit carbonic anhydrase hCA I and hCA II isoenzymes, with IC50 values of 4.77 and 9.66 nM, respectively. hCA I-IN-3 can be used for cancer research.
    hCA I-IN-3
  • HY-137364
    Disulfamide
    		Inhibitor
    Disulfamide, an orally active diuretic, is a carbonic anhydrase inhibitor with the IC50 value of 0.07 μM. Disulfamide leads to diuresis by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal tubule.
    Disulfamide
  • HY-147829
    hCAXII-IN-2
    		Inhibitor
    hCAXII-IN-2 (compound 5i) is a potent human carbonic anhydrase XII (hCA XII) and hCA IX inhibitor with Ki values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II.
    hCAXII-IN-2
  • HY-119919
    Clofenamide
    		Inhibitor
    Clofenamide (Aquedux) is a carbonic anhydrase (CA) inhibitor. Clofenamide exhibits diuretic activity.
    Clofenamide
  • HY-155391
    hCA/Wnt/β-catenin-IN-1
    		Inhibitor 99.96%
    hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (Ki: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line.
    hCA/Wnt/β-catenin-IN-1
  • HY-113719
    VM4-037
    VM4-037 can be used for the synthesis of VM4-037(18F). VM4-037(18F) is a fluorinated PET imaging agent for carbonic anhydrase IX.
    VM4-037
  • HY-151578
    DPP IV/hCA II-IN-1
    		Inhibitor
    DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) inhibitor with an IC50 value of 0.049 μM for DPP IV and with Ki values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively.
    DPP IV/hCA II-IN-1
  • HY-110234
    Topiramate D12
    		Inhibitor
    Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate D12
  • HY-115984
    Carbonic anhydrase inhibitor 8
    		Inhibitor
    Carbonic anhydrase inhibitor 8 (compound R-13), a benzyl-derivative, is a potent human carbonic anhydrase (hCA) inhibitor with Ki values of 60.7 nM, 320.7 nM, 2298 nM for hCA I, hCA II, hCA IV, respectively.
    Carbonic anhydrase inhibitor 8
  • HY-151495
    CAII-IN-3
    		Inhibitor
    CAII-IN-3 (compound 3h), a thiosemicarbazones derivatives, is a potent carbonic anhydrase-II (CA-II) inhibitor with an IC50 value of 13.4 µM.
    CAII-IN-3
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Carbonic Anhydrase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.